Literature DB >> 17992285

How do HYNIC-conjugated peptides bind technetium? Insights from LC-MS and stability studies.

Robert C King1, M Bashir-Uddin Surfraz, Stefano C G Biagini, Philip J Blower, Stephen J Mather.   

Abstract

Hydrazinonicotinamide (HYNIC) is an established bifunctional complexing agent for technetium-99m ((99m)Tc) but the structure of the technetium coordination sphere remains uncertain. To gain further insight into this, we have prepared conjugates of HYNIC and hydrazinobenzoic acid (HYBA) with a model peptide, and radiolabelled them with (99m)Tc using three well-established co-ligand systems: EDDA, tricine and tricine-nicotinic acid. The labelled peptides were studied by LC-MS and by subjecting them to serum stability and protein binding assays. For each co-ligand system, HYNIC conjugates formed fewer and more stable labelled species than the corresponding HYBA conjugates. LC-MS analysis showed that all conjugates contained one hydrazine moiety bound to Tc, that binding of Tc to HYNIC-peptide and co-ligand occurs with displacement of 5H(+) indicating a Tc formal oxidation state of +5, and that the Tc has no oxo- or halide ligands. LC-MS also shows that complexes formed with the HYNIC conjugate contain fewer coordinating co-ligand molecules than the HYBA conjugate indicating that HYNIC is able to more effectively satisfy the coordination requirement of technetium, perhaps by binding in chelating mode.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17992285      PMCID: PMC2258084          DOI: 10.1039/b705111e

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  22 in total

1.  Synthesis and Characterization of Rhenium(III) and Technetium(III) Organohydrazide Chelate Complexes. Reactions of 2-Hydrazinopyridine with Complexes of Rhenium and Technetium.

Authors:  Melissa Hirsch-Kuchma; Terrence Nicholson; Alan Davison; William M. Davis; Alun G. Jones
Journal:  Inorg Chem       Date:  1997-07-16       Impact factor: 5.165

Review 2.  Evolution of Tc-99m in diagnostic radiopharmaceuticals.

Authors:  S Banerjee; M R Pillai; N Ramamoorthy
Journal:  Semin Nucl Med       Date:  2001-10       Impact factor: 4.446

3.  In vitro cell studies of technetium-99m labeled RGD-HYNIC peptide, a comparison of tricine and EDDA as co-ligands.

Authors:  Zi-Fen Su; Jiang He; Mary Rusckowski; Donald J Hnatowich
Journal:  Nucl Med Biol       Date:  2003-02       Impact factor: 2.408

4.  Technetium-99m-labeled hydrazino nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial infection.

Authors:  J W Babich; H Solomon; M C Pike; D Kroon; W Graham; M J Abrams; R G Tompkins; R H Rubin; A J Fischman
Journal:  J Nucl Med       Date:  1993-11       Impact factor: 10.057

5.  Nitriles form mixed-coligand complexes with (99m)Tc-HYNIC-peptide.

Authors:  Guozheng Liu; Charles Wescott; Aaron Sato; Yi Wang; Ning Liu; Yu-Min Zhang; Mary Rusckowski; Donald J Hnatowich
Journal:  Nucl Med Biol       Date:  2002-01       Impact factor: 2.408

6.  A novel ternary ligand system for 99mTc-labeling of hydrazino nicotinamide-modified biologically active molecules using imine-N-containing heterocycles as coligands.

Authors:  S Liu; D S Edwards; A R Harris
Journal:  Bioconjug Chem       Date:  1998 Sep-Oct       Impact factor: 4.774

7.  99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.

Authors:  E von Guggenberg; M Behe; T M Behr; M Saurer; T Seppi; C Decristoforo
Journal:  Bioconjug Chem       Date:  2004 Jul-Aug       Impact factor: 4.774

8.  Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.

Authors:  Martin Béhé; Wolfgang Becker; Martin Gotthardt; Christa Angerstein; Thomas M Behr
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-24       Impact factor: 9.236

9.  Relevance of Somatostatin Receptors and Other Peptide Receptors in Pathology.

Authors:  Jean Claude Reubi
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

Review 10.  Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002.

Authors:  Marion de Jong; Dik Kwekkeboom; Roelf Valkema; Eric P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-05       Impact factor: 9.236

View more
  14 in total

1.  Highlights of the annual congress of the European Association of Nuclear Medicine, Copenhagen 2007.

Authors:  Juhani Knuuti; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03       Impact factor: 9.236

2.  99mTc-HYNIC-spermine for imaging polyamine transport system-positive tumours: preclinical evaluation.

Authors:  Sabrina Pesnel; Yves Guminski; Arnaud Pillon; Stéphanie Lerondel; Thierry Imbert; Nicolas Guilbaud; Anna Kruczynski; Christian Bailly; Alain Le Pape
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06-10       Impact factor: 9.236

3.  In vitro and in vivo evaluation of melanin-binding decapeptide 4B4 radiolabeled with 177Lu, 166Ho, and 153Sm radiolanthanides for the purpose of targeted radionuclide therapy of melanoma.

Authors:  Beau Ballard; Zewei Jiang; Clifford E Soll; Ekaterina Revskaya; Cathy S Cutler; Ekaterina Dadachova; Lynn C Francesconi
Journal:  Cancer Biother Radiopharm       Date:  2011-10-04       Impact factor: 3.099

Review 4.  A nuclear chocolate box: the periodic table of nuclear medicine.

Authors:  Philip J Blower
Journal:  Dalton Trans       Date:  2015-03-21       Impact factor: 4.390

Review 5.  Radiolabeled apoptosis imaging agents for early detection of response to therapy.

Authors:  Kazuma Ogawa; Miho Aoki
Journal:  ScientificWorldJournal       Date:  2014-10-14

6.  Synthesis and preliminary evaluation of a new (99m)tc labeled substance p analogue as a potential tumor imaging agent.

Authors:  Saeed Mozaffari; Mostafa Erfani; Davood Beiki; Fariba Johari Daha; Farzad Kobarfard; Saeed Balalaie; Babak Fallahi
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

7.  Evaluation of a 99mTc-tricine Vascular Disrupting Agent as an In-vivo Imaging in 4T1 Mouse Breast Tumor Model.

Authors:  Mostafa Erfani; Seyed Pezhman Shirmardi; Mohammad Shafiei
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

8.  Opportunities and challenges for metal chemistry in molecular imaging: from gamma camera imaging to PET and multimodality imaging.

Authors:  Richard Southworth; Rafael Torres Martin de Rosales; Levente K Meszaros; Michelle T Ma; Gregory E D Mullen; Gilbert Fruhwirth; Jennifer D Young; Cinzia Imberti; Julia Bagunya-Torres; Erica Andreozzi; Philip J Blower
Journal:  Adv Inorg Chem       Date:  2015-11-16       Impact factor: 3.282

9.  Development and evaluation of a novel (99m)tc-labeled annexin A5 for early detection of response to chemotherapy.

Authors:  Kazuma Ogawa; Katsuichi Ohtsuki; Tomomi Shibata; Miho Aoki; Morio Nakayama; Yoji Kitamura; Masahiro Ono; Masashi Ueda; Tomoki Doue; Masahisa Onoguchi; Kazuhiro Shiba; Akira Odani
Journal:  PLoS One       Date:  2013-12-04       Impact factor: 3.240

10.  Rhenium and Technetium-oxo Complexes with Thioamide Derivatives of Pyridylhydrazine Bifunctional Chelators Conjugated to the Tumour Targeting Peptides Octreotate and Cyclic-RGDfK.

Authors:  Andrea J North; John A Karas; Michelle T Ma; Philip J Blower; Uwe Ackermann; Jonathan M White; Paul S Donnelly
Journal:  Inorg Chem       Date:  2017-08-02       Impact factor: 5.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.